Please login to the form below

Not currently logged in

Boyds appoints Dr Nick Meyers and Natasha Nesterova-Smith

Pharma and biotech consultancy company expands its senior team

Boyds has expanded its senior team, appointing Dr Nick Meyers as programme director and Nastasha Nesterova-Smith as an associate director in regulatory affairs.

Dr Meyers joined Boyds in January, having most recently held senior management positions with Daiichi Sankyo Development, CRO and PPD.

Having worked in the industry for over 20 years, Dr Meyers also brings experience from Phytopharm, where he worked on the treatment of Parkinson's disease and ALS, and Alizyme Therapeutics, where he was responsible for the development of treatment of IBS-C and IBS-A.

Meanwhile, Nesterova-Smith joined Boyds in December 2015 bringing experience as a regulatory professional at Amgen, Genzyme, Parexel, Transkaryotic Therapies and Wyeth.

She has over 14 years' regulatory experience in drug development and registrations for biological and small molecules, clinical development, MMA and lifecycle management for EU centrally approved products.

Alan Boyd, founder and chief executive officer of Boyd's, said: “We are experiencing a period of growth and seeing an increase in work over the past twelve months, particularly in the biological space. I am delighted to welcome Nick and Natasha to the team in support of this growth.”

15th January 2016

From: Regulatory



Featured jobs

Subscribe to our email news alerts


Add my company

Founded in 2002, Cactus Communications is a fully integrated, global scholarly communications company with offices in Japan, South Korea, India,...

Latest intelligence

Waking the sleeping giant
The lights are coming on for healthcare delivery in Africa...
How to get rep buy-in for multi-channel
How do you manage a team who may be resistant to change?...
Blog: Digital therapeutics: within our reach?
Digital therapeutics is a hot topic right now. By using digital technology to manage, treat or even prevent chronic conditions, digital therapeutics is promising to revolutionise healthcare. But is this...